Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Jun;43(6):1463-4.
doi: 10.1128/AAC.43.6.1463.

In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients

D J Hoban  1 , G G Zhanel, J A Karlowsky
Affiliations

In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients

D J Hoban et al. Antimicrob Agents Chemother. 1999 Jun.

Abstract

Fluconazole-resistant Candida albicans and intrinsically fluconazole-resistant Candida species have been reported as bloodstream isolates. However, an association between the isolation of fluconazole-resistant Candida from the bloodstream and patient risk factors for fungemia has not been established. The purpose of this study was to determine the prevalence of fluconazole resistance in bloodstream isolates of Candida species and Cryptococcus neoformans collected from patients with neutropenia, one of the most important risk factors for fungemia. MICs of voriconazole, fluconazole, itraconazole, ketoconazole, amphotericin B, and flucytosine were determined by the National Committee for Clinical Laboratory Standards M27-A method (1997). Voriconazole, on a per-weight basis, was the most active azole tested. Fluconazole resistance (MIC >/= 64 microg/ml) was not identified in any of the C. albicans (n = 513), Candida parapsilosis (n = 78), Candida tropicalis (n = 62), or C. neoformans (n = 38) isolates tested.

PubMed Disclaimer

References

    1. Karlowsky J A, Zhanel G G, Klym K A, Hoban D J, Kabani A M. Candidemia in a Canadian tertiary care hospital from 1976 to 1996. Diagn Microbiol Infect Dis. 1997;28:5–9. - PubMed
    1. Kauffman C A, Zarins L T. In vitro activity of voriconazole against Candida species. Diagn Microbiol Infect Dis. 1998;31:297–300. - PubMed
    1. Marco F, Pfaller M A, Messer S, Jones R N. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother. 1998;42:161–163. - PMC - PubMed
    1. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Tentative standard M27-A. Wayne, Pa: National Committee for Clinical Laboratory Standards; 1997.
    1. Nicolle L E, Rotstein C, Bourgault A M, St.-Germain G, Garber G the Canadian Infectious Diseases Society Invasive Fungal Registry. Invasive fungal infections in Canada from 1992 to 1994. Can J Infect Dis. 1998;9:347–352. - PMC - PubMed

Publication types

LinkOut - more resources